Therapeutic effects of computerized tomography (CT)-guided percutaneous microwave ablation on malignant lung tumors

Lung cancer is a common clinical malignancy. In this study, we aimed to evaluate the therapeutic effects of computerized tomography ()-guided percutaneous microwave ablation (MWA) on malignant lung tumors. Sixty patients in our hospital enrolled between January 2015 and January 2017 were picked up as subjects. They were allocated into control group (30 malignant lung cancer patients underwent chemotherapy) and observation group (thirty patients received CT-guided percutaneous MWA). Later, comparisons of the objective response rate, tumor markers in serum, prevalence rate of untoward effects, long-term survival rate, relapse rate and quality-of-life (QoL) score were implemented. MWA patients showed an objective response rate of 66.7% (the rate was 40.00% in chemotherapy group; P <0.05). Serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125) and CA153 had lower levels after MWA in both groups than those before MWA (P <0.05) (this tendency was especially striking in observation group; P <0.05). In MWA patients, totally 10.00% of patients showed untoward effects (this was 33.33% in chemotherapy patients; P <0.05). The QoL scores were higher after MWA in both groups than those before MWA (P <0.05), especially in the observation group (P <0.05). For patients with malignant lung tumors, CT-guided percutaneous MWA may augment the short-term efficacy, control the tumor progression, relieve the adverse reactions and long-term local recurrence, increase the survival rate for a long term and improve the QoL during survival.